• Explore /
  • Poster
  • / Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).

Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).

Abstract Poster

Authors

null

Paul L. de Souza

University of Western Sydney School of Medicine, Sydney, Australia

Paul L. de Souza , Shirley Wong , Sanjeev Sewak , Dusan Kotasek , Bhumsuk Keam , Jinsoo Chung , Noelle Erbeck , Jackie Han , Luca Dezzani , Qasim Ahmad , Paul N. Mainwaring

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT01545817

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 648)

DOI

10.1200/JCO.2018.36.6_suppl.648

Abstract #

648

Poster Bd #

H19

Abstract Disclosures

Similar Posters

First Author: Thomas Cosgriff

First Author: Thomas Cosgriff

First Author: Robert Motzer

First Author: Giuseppe Procopio